1
|
Heinzelbecker J, Fauskanger M, Jonson I, Krengel U, Løset GÅ, Munthe L, Tveita A. Chimeric antigen receptor T cells targeting the GM3(Neu5Gc) ganglioside. Front Immunol 2024; 15:1331345. [PMID: 38370401 PMCID: PMC10869436 DOI: 10.3389/fimmu.2024.1331345] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2023] [Accepted: 01/19/2024] [Indexed: 02/20/2024] Open
Abstract
Chimeric antigen receptor (CAR) T cell technology has ushered in a new era of immunotherapy, enabling the targeting of a broad range of surface antigens, surpassing the limitations of traditional T cell epitopes. Despite the wide range of non-protein tumor-associated antigens, the advancement in crafting CAR T cells for these targets has been limited. Owing to an evolutionary defect in the CMP-Neu5Ac hydroxylase (CMAH) that abolishes the synthesis of CMP-Neu5Gc from CMP-Neu5Ac, Neu5Gc is generally absent in human tissues. Despite this, Neu5Gc-containing antigens, including the ganglioside GM3(Neu5Gc) have consistently been observed on tumor cells across a variety of human malignancies. This restricted expression makes GM3(Neu5Gc) an appealing and highly specific target for immunotherapy. In this study, we designed and evaluated 14F7-28z CAR T cells, with a targeting unit derived from the GM3(Neu5Gc)-specific murine antibody 14F7. These cells exhibited exceptional specificity, proficiently targeting GM3(Neu5Gc)-expressing murine tumor cells in syngeneic mouse models, ranging from B cell malignancies to epithelial tumors, without compromising safety. Notably, human tumor cells enhanced with murine Cmah were effectively targeted and eliminated by the 14F7 CAR T cells. Nonetheless, despite the detectable presence of GM3(Neu5Gc) in unmodified human tumor xenografts, the levels were insufficient to trigger a tumoricidal T-cell response with the current CAR T cell configuration. Overall, our findings highlight the potential of targeting the GM3(Neu5Gc) ganglioside using CAR T cells across a variety of cancers and set the stage for the optimization of 14F7-based therapies for future human clinical application.
Collapse
Affiliation(s)
- Julia Heinzelbecker
- Department of Immunology and Transfusion Medicine, Oslo University Hospital, Oslo, Norway
- K.G. Jebsen Centre for B cell malignancies, University of Oslo, Oslo, Norway
| | - Marte Fauskanger
- K.G. Jebsen Centre for B cell malignancies, University of Oslo, Oslo, Norway
| | - Ida Jonson
- Department of Immunology and Transfusion Medicine, Oslo University Hospital, Oslo, Norway
| | - Ute Krengel
- Department of Chemistry, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway
| | - Geir Åge Løset
- Department of Biosciences, Faculty of Mathematics and Natural Sciences University of Oslo, Oslo, Norway
- Nextera AS, Oslo, Norway
| | - Ludvig Munthe
- K.G. Jebsen Centre for B cell malignancies, University of Oslo, Oslo, Norway
| | - Anders Tveita
- Department of Immunology and Transfusion Medicine, Oslo University Hospital, Oslo, Norway
- K.G. Jebsen Centre for B cell malignancies, University of Oslo, Oslo, Norway
| |
Collapse
|
2
|
Manni M, Mantuano NR, Zingg A, Kappos EA, Behrens AJ, Back J, Follador R, Faridmoayer A, Läubli H. Detection of N-glycolyl-neuraminic acid-containing glycolipids in human skin. Front Immunol 2023; 14:1291292. [PMID: 38094289 PMCID: PMC10716299 DOI: 10.3389/fimmu.2023.1291292] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/08/2023] [Accepted: 11/10/2023] [Indexed: 12/18/2023] Open
Abstract
Humans lack the enzyme that produces the sialic acid N-glycolyl neuraminic acid (Neu5Gc), but several lines of evidence have shown that Neu5Gc can be taken up by mammalian food sources and replace the common human sialic acid N-acetyl neuraminic acid (Neu5Ac) in glycans. Cancer tissue has been shown to have increased the presence of Neu5Gc and Neu5Gc-containing glycolipids such as the ganglioside GM3, which have been proposed as tumor-specific antigens for antibody treatment. Here, we show that a previously described antibody against Neu5Gc-GM3 is binding to Neu5GC-containing gangliosides and is strongly staining different cancer tissues. However, we also found a strong intracellular staining of keratinocytes of healthy skin. We confirmed this staining on freshly isolated keratinocytes by flow cytometry and detected Neu5Gc by mass spectrometry. This finding implicates that non-human Neu5Gc can be incorporated into gangliosides in human skin, and this should be taken into consideration when targeting Neu5Gc-containing gangliosides for cancer immunotherapy.
Collapse
Affiliation(s)
- Michela Manni
- Department of Biomedicine, University Hospital and University of Basel, Basel, Switzerland
- Glycoera AG, Wädenswil, Switzerland
| | | | - Andreas Zingg
- Department of Biomedicine, University Hospital and University of Basel, Basel, Switzerland
| | - Elisabeth A. Kappos
- Department of Plastic, Reconstructive, Aesthetic and Handsurgery, University Hospital and University of Basel, Basel, Switzerland
| | | | | | | | | | - Heinz Läubli
- Department of Biomedicine, University Hospital and University of Basel, Basel, Switzerland
- Division of Oncology, University Hospital Basel, Basel, Switzerland
| |
Collapse
|
3
|
Bousquet PA, Manna D, Sandvik JA, Arntzen MØ, Moreno E, Sandvig K, Krengel U. SILAC-based quantitative proteomics and microscopy analysis of cancer cells treated with the N-glycolyl GM3-specific anti-tumor antibody 14F7. Front Immunol 2022; 13:994790. [PMID: 36439103 PMCID: PMC9682173 DOI: 10.3389/fimmu.2022.994790] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2022] [Accepted: 10/20/2022] [Indexed: 08/11/2024] Open
Abstract
Cancer immunotherapy represents a promising approach to specifically target and treat cancer. The most common mechanisms by which monoclonal antibodies kill cells include antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity and apoptosis, but also other mechanisms have been described. 14F7 is an antibody raised against the tumor-associated antigen NeuGc GM3, which was previously reported to kill cancer cells without inducing apoptotic pathways. The antibody was reported to induce giant membrane lesions in tumor cells, with apparent changes in the cytoskeleton. Here, we investigated the effect of humanized 14F7 on HeLa cells using stable isotope labeling with amino acids in cell culture (SILAC) in combination with LC-MS and live cell imaging. 14F7 did not kill the HeLa cells, however, it caused altered protein expression (MS data are available via ProteomeXchange with identifier PXD024320). Several cytoskeletal and nucleic-acid binding proteins were found to be strongly down-regulated in response to antibody treatment, suggesting how 14F7 may induce membrane lesions in cells that contain higher amounts of NeuGc GM3. The altered expression profile identified in this study thus contributes to an improved understanding of the unusual killing mechanism of 14F7.
Collapse
Affiliation(s)
| | - Dipankar Manna
- Department of Chemistry, University of Oslo, Oslo, Norway
| | | | | | - Ernesto Moreno
- Facultad de Ciencias Básicas, Universidad de Medellín, Medellín, Colombia
| | - Kirsten Sandvig
- Department of Biosciences, University of Oslo, Oslo, Norway
- Department of Molecular Cell Biology, Institute for Cancer Research, The Norwegian Radium Hospital, Oslo, Norway
- Centre for Cancer Cell Reprogramming, Faculty of Medicine, University of Oslo, Oslo, Norway
| | - Ute Krengel
- Department of Chemistry, University of Oslo, Oslo, Norway
| |
Collapse
|
4
|
Cribioli E, Giordano Attianese GMP, Coukos G, Irving M. CAR T cells targeting the ganglioside NGcGM3 control ovarian tumors in the absence of toxicity against healthy tissues. Front Immunol 2022; 13:951143. [PMID: 35990626 PMCID: PMC9389107 DOI: 10.3389/fimmu.2022.951143] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2022] [Accepted: 06/30/2022] [Indexed: 11/30/2022] Open
Abstract
Chimeric antigen receptor (CAR) T cells have emerged as a powerful immunotherapeutic tool against certain hematological malignancies but a significant proportion of patients either do not respond or they relapse, sometimes as a result of target antigen loss. Moreover, limited clinical benefit has been reported for CAR therapy against epithelial derived solid tumors. A major reason for this is the paucity of solid tumor antigens identified to date that are broadly, homogeneously and stably expressed but not found on healthy tissues. To address this, here we describe the development and evaluation of CAR T cells directed against N-glycoslylated ganglioside monosialic 3 (NGcGM3). NGcGM3 derives from the enzymatic hydroxylation of N-acetylneuraminic acid (NAc) GM3 (NAcGM3) and it is present on the surface of a range of cancers including ovarian, breast, melanoma and lymphoma. However, while NAcGM3 is found on healthy human cells, NGcGM3 is not due to the 7deletion of an exon in the gene encoding for the enzyme cytidine monophospho-N-acetylneuraminic acid hydroxylase (CMAH). Indeed, unlike for most mammals, in humans NGcGM3 is considered a neoantigen as its presence on tumors is the result of metabolic incorporation from dietary sources. Here, we have generated 3 CARs comprising different single chain variable fragments (scFvs) originating from the well-characterized monoclonal antibody (mAb) 14F7. We show reactivity of the CAR T cells against a range of patient tumor fragments and we demonstrate control of NGcGM3+ SKOV3 ovarian tumors in the absence of toxicity despite the expression of CMAH and presence of NGcGM3+ on healthy tissues in NSG mice. Taken together, our data indicate clinical potential for 14F7-based CAR T cells against a range of cancers, both in terms of efficacy and of patient safety.
Collapse
|
5
|
Understanding and Modulating Antibody Fine Specificity: Lessons from Combinatorial Biology. Antibodies (Basel) 2022; 11:antib11030048. [PMID: 35892708 PMCID: PMC9326607 DOI: 10.3390/antib11030048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2022] [Revised: 07/08/2022] [Accepted: 07/11/2022] [Indexed: 02/01/2023] Open
Abstract
Combinatorial biology methods such as phage and yeast display, suitable for the generation and screening of huge numbers of protein fragments and mutated variants, have been useful when dissecting the molecular details of the interactions between antibodies and their target antigens (mainly those of protein nature). The relevance of these studies goes far beyond the mere description of binding interfaces, as the information obtained has implications for the understanding of the chemistry of antibody–antigen binding reactions and the biological effects of antibodies. Further modification of the interactions through combinatorial methods to manipulate the key properties of antibodies (affinity and fine specificity) can result in the emergence of novel research tools and optimized therapeutics.
Collapse
|
6
|
Bjerregaard-Andersen K, Abraha F, Johannesen H, Oscarson S, Moreno E, Krengel U. Key role of a structural water molecule for the specificity of 14F7-An antitumor antibody targeting the NeuGc GM3 ganglioside. Glycobiology 2021; 31:1500-1509. [PMID: 34735569 PMCID: PMC8684480 DOI: 10.1093/glycob/cwab076] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2021] [Revised: 06/19/2021] [Accepted: 06/28/2021] [Indexed: 12/22/2022] Open
Abstract
Tumor-associated glycolipids such as NeuGc GM3 are auspicious molecular targets in antineoplastic therapies and vaccine strategies. 14F7 is a monoclonal IgG1 with high clinical potential in cancer immunotherapy as it displays extraordinary specificity for NeuGc GM3, while it does not recognize the very similar, ubiquitous NeuAc GM3. Here we present the 2.3 Å crystal structure of the 14F7 antigen-binding domain (14F7 scFv) in complex with the NeuGc GM3 trisaccharide. Modeling analysis and previous mutagenesis data suggest that 14F7 may also bind to an alternative NeuGc GM3 conformation, not observed in the crystal structure. The most intriguing finding, however, was that a water molecule centrally placed in the complementarity-determining region directly mediates the specificity of 14F7 to NeuGc GM3. This has profound impact on the complexity of engineering in the binding site and provides an excellent example of the importance in understanding the water structure in antibody-antigen interactions.
Collapse
Affiliation(s)
| | - Fana Abraha
- School of Chemistry, University College Dublin, Belfield, Dublin 4, Ireland.,Recipharm OT Chemistry, Uppsala, Sweden
| | - Hedda Johannesen
- Department of Chemistry, University of Oslo, NO-0315 Oslo, Norway.,Department of Biosciences, University of Oslo, NO-0316 Oslo, Norway
| | - Stefan Oscarson
- School of Chemistry, University College Dublin, Belfield, Dublin 4, Ireland
| | - Ernesto Moreno
- Facultad de Ciencias Básicas, Universidad de Medellín, Medellín 050026, Colombia
| | - Ute Krengel
- Department of Chemistry, University of Oslo, NO-0315 Oslo, Norway
| |
Collapse
|
7
|
Pore-forming toxins from sea anemones: from protein-membrane interaction to its implications for developing biomedical applications. ADVANCES IN BIOMEMBRANES AND LIPID SELF-ASSEMBLY 2020. [DOI: 10.1016/bs.abl.2020.02.005] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
8
|
Directed evolution of super-secreted variants from phage-displayed human Interleukin-2. Sci Rep 2019; 9:800. [PMID: 30692603 PMCID: PMC6349883 DOI: 10.1038/s41598-018-37280-5] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2018] [Accepted: 11/30/2018] [Indexed: 11/30/2022] Open
Abstract
Selection from a phage display library derived from human Interleukin-2 (IL-2) yielded mutated variants with greatly enhanced display levels of the functional cytokine on filamentous phages. Introduction of a single amino acid replacement selected that way (K35E) increased the secretion levels of IL-2-containing fusion proteins from human transfected host cells up to 20-fold. Super-secreted (K35E) IL-2/Fc is biologically active in vitro and in vivo, has anti-tumor activity and exhibits a remarkable reduction in its aggregation propensity- the major manufacturability issue limiting IL-2 usefulness up to now. Improvement of secretion was also shown for a panel of IL-2-engineered variants with altered receptor binding properties, including a selective agonist and a super agonist that kept their unique properties. Our findings will improve developability of the growing family of IL-2-derived immunotherapeutic agents and could have a broader impact on the engineering of structurally related four-alpha-helix bundle cytokines.
Collapse
|
9
|
Grzeschik J, Yanakieva D, Roth L, Krah S, Hinz SC, Elter A, Zollmann T, Schwall G, Zielonka S, Kolmar H. Yeast Surface Display in Combination with Fluorescence‐activated Cell Sorting Enables the Rapid Isolation of Antibody Fragments Derived from Immunized Chickens. Biotechnol J 2018; 14:e1800466. [DOI: 10.1002/biot.201800466] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2018] [Revised: 10/11/2018] [Indexed: 12/13/2022]
Affiliation(s)
- Julius Grzeschik
- Institute for Organic Chemistry and BiochemistryTechnische Universität DarmstadtAlarich‐Weiss‐Strasse 4D‐64287 DarmstadtGermany
- Merck Lab @ Technische Universität DarmstadtAlarich‐Weiss‐Strasse 8, D‐64287DarmstadtGermany
| | - Desislava Yanakieva
- Institute for Organic Chemistry and BiochemistryTechnische Universität DarmstadtAlarich‐Weiss‐Strasse 4D‐64287 DarmstadtGermany
- Merck Lab @ Technische Universität DarmstadtAlarich‐Weiss‐Strasse 8, D‐64287DarmstadtGermany
| | - Lukas Roth
- Protein Engineering and Antibody TechnologiesMerck KGaAFrankfurter Strasse 250, D‐64293DarmstadtGermany
| | - Simon Krah
- Protein Engineering and Antibody TechnologiesMerck KGaAFrankfurter Strasse 250, D‐64293DarmstadtGermany
| | - Steffen C. Hinz
- Institute for Organic Chemistry and BiochemistryTechnische Universität DarmstadtAlarich‐Weiss‐Strasse 4D‐64287 DarmstadtGermany
- Merck Lab @ Technische Universität DarmstadtAlarich‐Weiss‐Strasse 8, D‐64287DarmstadtGermany
| | - Adrian Elter
- Institute for Organic Chemistry and BiochemistryTechnische Universität DarmstadtAlarich‐Weiss‐Strasse 4D‐64287 DarmstadtGermany
- Merck Lab @ Technische Universität DarmstadtAlarich‐Weiss‐Strasse 8, D‐64287DarmstadtGermany
| | - Tina Zollmann
- Science RelationsMerck KGaAFrankfurter Strasse 250, D‐64293DarmstadtGermany
- Merck Lab @ Technische Universität DarmstadtAlarich‐Weiss‐Strasse 8, D‐64287DarmstadtGermany
| | - Gerhard Schwall
- Science RelationsMerck KGaAFrankfurter Strasse 250, D‐64293DarmstadtGermany
- Merck Lab @ Technische Universität DarmstadtAlarich‐Weiss‐Strasse 8, D‐64287DarmstadtGermany
| | - Stefan Zielonka
- Protein Engineering and Antibody TechnologiesMerck KGaAFrankfurter Strasse 250, D‐64293DarmstadtGermany
| | - Harald Kolmar
- Institute for Organic Chemistry and BiochemistryTechnische Universität DarmstadtAlarich‐Weiss‐Strasse 4D‐64287 DarmstadtGermany
- Merck Lab @ Technische Universität DarmstadtAlarich‐Weiss‐Strasse 8, D‐64287DarmstadtGermany
| |
Collapse
|
10
|
Bjerregaard-Andersen K, Johannesen H, Abdel-Rahman N, Heggelund JE, Hoås HM, Abraha F, Bousquet PA, Høydahl LS, Burschowsky D, Rojas G, Oscarson S, Løset GÅ, Krengel U. Crystal structure of an L chain optimised 14F7 anti-ganglioside Fv suggests a unique tumour-specificity through an unusual H-chain CDR3 architecture. Sci Rep 2018; 8:10836. [PMID: 30022069 PMCID: PMC6052152 DOI: 10.1038/s41598-018-28918-5] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/10/2018] [Accepted: 06/28/2018] [Indexed: 12/13/2022] Open
Abstract
Targeted cancer immunotherapy offers increased efficacy concomitantly with reduced side effects. One antibody with promising clinical potential is 14F7, which specifically recognises the NeuGc GM3 ganglioside. This antigen is found in the plasma membrane of a range of tumours, but is essentially absent from healthy human cells. 14F7 can discriminate NeuGc GM3 from the very similar NeuAc GM3, a common component of cell membranes. The molecular basis for this unique specificity is poorly understood. Here we designed and expressed 14F7-derived single-chain Fvs (scFvs), which retained the specificity of the parent antibody. Detailed expression and purification protocols are described as well as the synthesis of the NeuGc GM3 trisaccharide. The most successful scFv construct, which comprises an alternative variable light chain (VLA), allowed structure determination to 2.2 Å resolution. The structure gives insights into the conformation of the important CDR H3 loop and the suspected antigen binding site. Furthermore, the presence of VLA instead of the original VL elucidates how this subdomain indirectly stabilises the CDR H3 loop. The current work may serve as a guideline for the efficient production of scFvs for structure determination.
Collapse
Affiliation(s)
| | - Hedda Johannesen
- Department of Chemistry, University of Oslo, NO-0315 Oslo, Norway
| | - Noha Abdel-Rahman
- Department of Chemistry, University of Oslo, NO-0315 Oslo, Norway.,Department of Biochemistry, Faculty of Pharmacy, Mansoura University, Mansoura, 35516, Egypt
| | - Julie Elisabeth Heggelund
- Department of Chemistry, University of Oslo, NO-0315 Oslo, Norway.,School of Biomedical Sciences, University of Leeds, Leeds, LS2 9JT, UK
| | | | - Fana Abraha
- School of Chemistry, University College Dublin, Belfield, Dublin, 4, Ireland
| | - Paula A Bousquet
- Department of Chemistry, University of Oslo, NO-0315 Oslo, Norway
| | - Lene Støkken Høydahl
- Centre for Immune Regulation and Department of Immunology, University of Oslo and Oslo University Hospital, NO-0372 Oslo, Norway
| | - Daniel Burschowsky
- Department of Chemistry, University of Oslo, NO-0315 Oslo, Norway.,Leicester Institute of Structural and Chemical Biology, University of Leicester, Leicester, LE1 7HB, UK
| | - Gertrudis Rojas
- Center of Molecular Immunology, Calle 216 esq 15, Atabey, Playa, La Habana, CP, 11300, Cuba
| | - Stefan Oscarson
- School of Chemistry, University College Dublin, Belfield, Dublin, 4, Ireland
| | - Geir Åge Løset
- Centre for Immune Regulation and Department of Immunology, University of Oslo and Oslo University Hospital, NO-0372 Oslo, Norway. .,Department of Biosciences, University of Oslo, NO-0316 Oslo, Norway. .,Nextera AS, NO-0349 Oslo, Norway.
| | - Ute Krengel
- Department of Chemistry, University of Oslo, NO-0315 Oslo, Norway.
| |
Collapse
|
11
|
Liu Y, Lin M, Wu J, Hu X, Zhang X, Xu C, Zhong J, Xie Y, Zhang C, Luo C, Liu X. Generation of panels of anti-idiotypic single-chain variable fragments mimicking Cry2Aa toxin using the chain shuffling technique. FOOD AGR IMMUNOL 2018. [DOI: 10.1080/09540105.2018.1440535] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Affiliation(s)
- Yuan Liu
- Key Laboratory of Food Quality and Safety of Jiangsu Province, Jiangsu Academy of Agricultural Sciences, Nanjing, People’s Republic of China
| | - Manman Lin
- Key Laboratory of Food Quality and Safety of Jiangsu Province, Jiangsu Academy of Agricultural Sciences, Nanjing, People’s Republic of China
| | - Jiaxin Wu
- Key Laboratory of Food Quality and Safety of Jiangsu Province, Jiangsu Academy of Agricultural Sciences, Nanjing, People’s Republic of China
| | - Xiaodan Hu
- Key Laboratory of Food Quality and Safety of Jiangsu Province, Jiangsu Academy of Agricultural Sciences, Nanjing, People’s Republic of China
| | - Xiao Zhang
- Key Laboratory of Food Quality and Safety of Jiangsu Province, Jiangsu Academy of Agricultural Sciences, Nanjing, People’s Republic of China
| | - Chongxin Xu
- Key Laboratory of Food Quality and Safety of Jiangsu Province, Jiangsu Academy of Agricultural Sciences, Nanjing, People’s Republic of China
| | - Jianfeng Zhong
- Key Laboratory of Food Quality and Safety of Jiangsu Province, Jiangsu Academy of Agricultural Sciences, Nanjing, People’s Republic of China
| | - Yajing Xie
- Key Laboratory of Food Quality and Safety of Jiangsu Province, Jiangsu Academy of Agricultural Sciences, Nanjing, People’s Republic of China
| | - Cunzheng Zhang
- Key Laboratory of Food Quality and Safety of Jiangsu Province, Jiangsu Academy of Agricultural Sciences, Nanjing, People’s Republic of China
| | - Chuping Luo
- Huaiyin Institute of Technology, Huaian, People’s Republic of China
| | - Xianjin Liu
- Key Laboratory of Food Quality and Safety of Jiangsu Province, Jiangsu Academy of Agricultural Sciences, Nanjing, People’s Republic of China
| |
Collapse
|
12
|
Bousquet PA, Sandvik JA, Jeppesen Edin NF, Krengel U. Hypothesis: Hypoxia induces de novo synthesis of NeuGc gangliosides in humans through CMAH domain substitute. Biochem Biophys Res Commun 2017; 495:1562-1566. [PMID: 29196263 DOI: 10.1016/j.bbrc.2017.11.183] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2017] [Accepted: 11/28/2017] [Indexed: 12/27/2022]
Abstract
Immunotherapy is a growing field in cancer research. A privileged tumor-associated antigen that has received much attention is N-glycolyl (NeuGc) GM3. This ganglioside is present in several types of cancer, but is almost undetectable in human healthy tissues. However, its non-hydroxylated variant, NeuAc GM3, is abundant in all mammals. Due to a deletion in the human gene encoding the key enzyme for synthesis of NeuGc, humans, in contrast to other mammals, cannot synthesize NeuGc GM3. Therefore the presence of this ganglioside in human cancer cells represents an enigma. It has been shown that hypoxic conditions trigger the expression of NeuGc gangliosides, which not only serve as attractive targets for cancer therapy, but also as diagnostic and prognostic tumor marker. Here, we confirm hypoxia-induced expression of the NeuGc GM3 ganglioside also in HeLa cells and reveal several candidate proteins, in particular GM3 synthase and subunit B of respiratory complex II (SDHB), that may be involved in the generation of NeuGc GM3 by SILAC-based proteome analysis. These findings have the potential to significantly advance our understanding of how this enigmatic tumor-associated antigen is produced in humans, and also suggest a possible mechanism of action of anti-tumor antibodies that recognize hypoxia markers, such as 14F7.
Collapse
Affiliation(s)
- Paula A Bousquet
- Department of Chemistry, University of Oslo, P.O. Box 1033 Blindern, NO-0315 Oslo, Norway.
| | - Joe Alexander Sandvik
- Department of Physics, University of Oslo, P.O. Box 1048 Blindern, NO-0315 Oslo, Norway
| | - Nina F Jeppesen Edin
- Department of Physics, University of Oslo, P.O. Box 1048 Blindern, NO-0315 Oslo, Norway
| | - Ute Krengel
- Department of Chemistry, University of Oslo, P.O. Box 1033 Blindern, NO-0315 Oslo, Norway.
| |
Collapse
|
13
|
Lamdan H, Gavilondo JV, Muñoz Y, Pupo A, Huerta V, Musacchio A, Pérez L, Ayala M, Rojas G, Balint RF, Larrick JW. Affinity maturation and fine functional mapping of an antibody fragment against a novel neutralizing epitope on human vascular endothelial growth factor. MOLECULAR BIOSYSTEMS 2013; 9:2097-106. [PMID: 23702826 DOI: 10.1039/c3mb70136k] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
We have previously reported the isolation of a novel single-chain variable fragment (scFv) against vascular endothelial growth factor (VEGF), from a phage-displayed human antibody repertoire. This scFv, denominated 2H1, was shown to block the binding of VEGF to its receptor but exhibited a moderate binding affinity. Here, we describe the affinity maturation of the 2H1 scFv. Two phage-displayed libraries were constructed by diversification of the third complementarity-determining regions (CDRs) of the light (VL) and heavy (VH) chain variable domains of 2H1 using parsimonious mutagenesis. A competitive phage-selection strategy in the presence of the parental scFv as a competitor was used to eliminate low affinity binders. High affinity variants were retrieved from both libraries. An optimized VL variant was designed and constructed by combining recurrent replacements found among selected variants in a single molecule, resulting in an additional affinity increase. Further affinity improvements were achieved by combining this optimized VL with the best VH variants. The final variant obtained here, L3H6, showed an overall affinity improvement of 18-fold over the parental scFv and exhibited an enhanced potency to block the binding of VEGF to its receptor. Using phage display and extensive mutagenesis of VEGF, we determined the fine specificity of L3H6. This functional mapping revealed a novel neutralizing epitope on human VEGF defined by the residues Y25, T71, E72, N100, K101, E103 and R105. The conformational epitope recognized by L3H6 was recapitulated by grafting human VEGF residues into the mouse molecule, providing further confirmation of the nature of the identified epitope.
Collapse
Affiliation(s)
- Humberto Lamdan
- Recombinant Antibodies Laboratory, Cancer Research Department, Center for Genetic Engineering and Biotechnology, PO Box 6162, Ave. 31 e/ 158 y 190, Cubanacan, Playa, La Habana, CP 10600, Cuba.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Rojas G, Pupo A, Gómez S, Krengel U, Moreno E. Engineering the binding site of an antibody against N-glycolyl GM3: from functional mapping to novel anti-ganglioside specificities. ACS Chem Biol 2013; 8:376-86. [PMID: 23138862 DOI: 10.1021/cb3003754] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
The structurally related gangliosides N-glycolyl GM3 and N-acetyl GM3 are potential targets for tumor immunotherapy. 14F7 is a monoclonal antibody able to discriminate the tumor-specific antigen N-glycolyl GM3 from the closely related N-acetyl GM3 on the basis of the presence of a single additional hydroxyl group in the former. A combinatorial phage display strategy, based on the screening of a large library followed by refined mutagenesis, allowed a thorough exploration of the binding chemistry of this unique antibody. Three essential features of the heavy chain variable region were identified: two aromatic rings (in positions 33 and 100D) contributing to the binding site architecture and an arginine residue (position 98) critical for recognition. Directed evolution of 14F7 resulted in novel variants that cross-react with the tumor-associated antigen N-acetyl GM3 and display recurrent replacements: the substitution W33Q and the appearance of additional arginine residues at several positions of CDR H1. Successful conversion of such engineered variable regions into whole cross-reactive anti-GM3 immunoglobulins validated our phage-based approach to study and modify the lead antibody 14F7. The resulting family of closely related antibodies offers new tools to study the mechanisms of cell death induced by antibodies targeting gangliosides. In vitro directed evolution was useful to overcome the technical limitations to obtain anti-ganglioside antibodies. The case of 14F7 illustrates the power of combining library screening with focused site-directed randomization for a comprehensive scanning of protein interactions.
Collapse
Affiliation(s)
- Gertrudis Rojas
- Center of Molecular Immunology, Calle 216 esq 15, Atabey, Playa, PO Box
16040, La Habana CP 11600, Cuba
| | - Amaury Pupo
- Center of Molecular Immunology, Calle 216 esq 15, Atabey, Playa, PO Box
16040, La Habana CP 11600, Cuba
| | - Silvia Gómez
- Center of Molecular Immunology, Calle 216 esq 15, Atabey, Playa, PO Box
16040, La Habana CP 11600, Cuba
| | - Ute Krengel
- Department of Chemistry, University of Oslo, PO Box 1033 Blindern, NO-0315 Oslo,
Norway
| | - Ernesto Moreno
- Center of Molecular Immunology, Calle 216 esq 15, Atabey, Playa, PO Box
16040, La Habana CP 11600, Cuba
| |
Collapse
|
15
|
Qi H, Lu H, Qiu HJ, Petrenko V, Liu A. Phagemid Vectors for Phage Display: Properties, Characteristics and Construction. J Mol Biol 2012; 417:129-43. [PMID: 22310045 DOI: 10.1016/j.jmb.2012.01.038] [Citation(s) in RCA: 97] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2011] [Revised: 01/20/2012] [Accepted: 01/24/2012] [Indexed: 11/20/2022]
Affiliation(s)
- Huan Qi
- Qingdao Institute of Bioenergy and Bioprocess Technology, Chinese Academy of Sciences, Qingdao 266101, China
| | | | | | | | | |
Collapse
|
16
|
A cytotoxic humanized anti-ganglioside antibody produced in a murine cell line defective of N-glycolylated-glycoconjugates. Immunobiology 2011; 216:1239-47. [DOI: 10.1016/j.imbio.2011.07.004] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2010] [Accepted: 07/03/2011] [Indexed: 11/19/2022]
|
17
|
Abstract
Phage display technology is an emerging drug discovery tool. Using that approach, short peptides that mimic part of a carbohydrate's conformation are selected by screening a peptide-displaying phage library with anti-carbohydrate antibodies. Chemically synthesized peptides with an identified sequence have been used as an alternative ligand to carbohydrate-binding proteins. These peptides represent research tools useful to assay the activities of glycosyltransferases and/or sulfotransferases or to inhibit the carbohydrate-dependent binding of proteins in vitro and in vivo. Peptides can also serve as immunogens to raise anti-carbohydrate antibodies in vivo in animals. Phage display has also been used in single-chain antibody technology by inserting an immunoglobulin's variable region sequence into the phage. A single-chain antibody library can then be screened with a carbohydrate antigen as the target, resulting in a recombinant anti-carbohydrate antibody with high affinity to the antigen. This review provides examples of successful applications of peptide-displaying phage technology to glycobiology. Such an approach should benefit translational research by supplying carbohydrate-mimetic peptides and carbohydrate-binding polypeptides.
Collapse
Affiliation(s)
- Michiko N Fukuda
- Cancer Center, Sanford-Burnham Medical Research Institute, La Jolla, CA 92037, USA.
| |
Collapse
|
18
|
Flicker S, Gadermaier E, Madritsch C, Valenta R. Passive immunization with allergen-specific antibodies. Curr Top Microbiol Immunol 2011; 352:141-59. [PMID: 21681684 DOI: 10.1007/82_2011_143] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
The induction of allergen-specific IgG antibodies has been identified as a major mechanism responsible for the reduction of allergic inflammation in allergic patients treated by allergen-specific immunotherapy. Several studies suggest that allergen-specific IgG antibodies induced by vaccination with allergens block mast cell and basophil degranulation, IgE-facilitated allergen presentation to T cells and IgE production. The availability of recombinant allergens and technologies for the production of recombinant human antibodies allows engineering of allergen-specific antibodies which can be used for passive immunization (i.e., therapy) and eventually for the prevention of allergy (i.e., prophylaxis). This chapter summarizes data supporting the possible use of allergen-specific antibodies for treatment and prophylaxis. Finally, concrete approaches for the treatment and prevention of allergy based on blocking antibodies are envisioned.
Collapse
Affiliation(s)
- Sabine Flicker
- Division of Immunopathology, Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Vienna General Hospital, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
| | | | | | | |
Collapse
|
19
|
Fitzgerald J, Leonard P, Darcy E, Danaher M, O'Kennedy R. Light-chain shuffling from an antigen-biased phage pool allows 185-fold improvement of an anti-halofuginone single-chain variable fragment. Anal Biochem 2010; 410:27-33. [PMID: 21078281 DOI: 10.1016/j.ab.2010.11.009] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2010] [Revised: 10/06/2010] [Accepted: 11/04/2010] [Indexed: 10/18/2022]
Abstract
Halofuginone is an antiprotozoal drug used in the treatment of coccidiosis in poultry, a contagious enteric disease caused by parasites of the Eimeria spp. To ensure that food is free from any halofuginone residues and safe for human consumption, a rapid method to detect these residues below the maximum residue limits (MRLs) in a variety of matrices is necessary. To address this need, we constructed an immune single-chain variable fragment (scFv) library from the RNA of a halofuginone-immunized chicken and selected halofuginone-specific scFv by phage display. The best clone isolated from the library had a limit of detection of 30 ng/ml as determined by enzyme-linked immunosorbent assay (ELISA). However, the minimum MRL for halofuginone in certain foodstuffs can be as low as 1 ng/ml, well below the sensitivity of the selected antibody. The selected antibody was then affinity maturated by light-chain shuffling to further improve the antibody's assay performance. The halofuginone-specific heavy-chain pool of the biopanned library was assembled with the light-chain repertoire amplified from the original prepanned library. This resulted in a heavy-chain-biased library from which an scFv with the potential to detect halofuginone residues as low as 80 pg/ml was isolated, a 185-fold improvement over the original scFv. This new chain-shuffled scFv was incorporated into a validated ELISA (according to Commission Regulation 2002/657/EC) for the sensitive detection of halofuginone in spiked processed egg samples.
Collapse
Affiliation(s)
- Jenny Fitzgerald
- School of Biotechnology and National Centre for Sensor Research, Dublin City University, Dublin 9, Ireland
| | | | | | | | | |
Collapse
|
20
|
Talavera A, Eriksson A, Okvist M, López-Requena A, Fernández-Marrero Y, Pérez R, Moreno E, Krengel U. Crystal structure of an anti-ganglioside antibody, and modelling of the functional mimicry of its NeuGc-GM3 antigen by an anti-idiotypic antibody. Mol Immunol 2009; 46:3466-75. [PMID: 19748674 DOI: 10.1016/j.molimm.2009.07.032] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2009] [Revised: 07/24/2009] [Accepted: 07/28/2009] [Indexed: 11/19/2022]
Abstract
N-Glycolylated (NeuGc) gangliosides are tumor-specific antigens and as such represent attractive targets for cancer immunotherapy. The chimeric antibody chP3 selectively recognizes a broad variety of NeuGc gangliosides, showing no cross-reactivity to the highly similar N-acetylated (NeuAc) gangliosides that are common cellular antigens in humans. Here, we report the crystal structure of the chP3 Fab and its computer-docking model with the trisaccharide NeuGcalpha3Galbeta4Glcbeta, which represents the carbohydrate moiety of the tumor-antigen NeuGc-GM3. The interaction involves only the heavy chain of the chP3 antibody. The modelled complex is consistent with all available experimental data and shows good surface complementarity. The negatively charged sialic acid residue NeuGc is buried in a pocket flanked by two arginine residues, VH Arg31 and VH Arg100A. We have further investigated the interaction of chP3 with its anti-idiotypic antibody, 1E10 (also known as Racotumomab), currently in clinical trials as a cancer vaccine. While many of the chP3 residues predicted to interact with the NeuGc ganglioside also feature prominently in the modelled complex of chP3 and 1E10, we do not observe structural mimicry. Rather, we suspect that the anti-idiotype 1E10 may serve as an imprint of the structural characteristics of the chP3 idiotype and, consequently, give rise to antibodies with P3-like properties upon immunization.
Collapse
|
21
|
Christensen PA, Danielczyk A, Ravn P, Larsen M, Stahn R, Karsten U, Goletz S. Modifying Antibody Specificity by Chain Shuffling of VH / VLbetween Antibodies with Related Specificities. Scand J Immunol 2009; 69:1-10. [DOI: 10.1111/j.1365-3083.2008.02164.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
|
22
|
Matsubara T, Iida M, Tsumuraya T, Fujii I, Sato T. Selection of a carbohydrate-binding domain with a helix-loop-helix structure. Biochemistry 2008; 47:6745-51. [PMID: 18540680 DOI: 10.1021/bi8000837] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
We obtained a novel carbohydrate-binding peptide having a helix-loop-helix scaffold from a random peptide library. The helix-loop-helix peptide library randomized at five amino acid residues was displayed on the major coat protein of a filamentous phage. Affinity selection with a ganglioside, Galbeta1-3GalNAcbeta1-4(Neu5Acalpha2-3)Galbeta1-4Glcbeta1-1'Cer (GM1), gave positive phage clones. Surface plasmon resonance spectroscopy showed that a corresponding 35-mer synthetic peptide had high affinity for GM1 with a dissociation constant of 0.24 microM. This peptide preferentially binds to GM1 rather than asialo GM1 and GM2, suggesting that a terminal galactose and sialic acid are required for the binding as for cholera toxin. Circular dichroism spectroscopic studies indicated that a helical structure is important for the affinity and specificity. Furthermore, alanine scanning at randomized positions showed that arginine and phenylalanine play an especially important role in the recognition of carbohydrates. Such a de novo helix-loop-helix peptide would be available for the design of carbohydrate-binding proteins.
Collapse
|
23
|
Zhou F, Ren JL, Dong J. Advances of candidate binding protein to envelope protein of hepatitis B virus. Shijie Huaren Xiaohua Zazhi 2008; 16:1788-1792. [DOI: 10.11569/wcjd.v16.i16.1788] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
There are at least 4 initial coding positions in S gene of hepatitis B virus (HBV), encoding pre-pre-S, pre-S1, pre-S2 as well as major protein. There are no definite evidences to prove that envelope protein will interact with human cellular protein. This review focused on research approaches to the existing protein - protein interaction and summarized proteins of liver cells that may interact with current HBV envelope protein. However, most of currently available results need further verification.
Collapse
|
24
|
Matsubara T, Sato T. Identification of Oligosaccharide-Recognition Molecules by Phage-Display Technology. TRENDS GLYCOSCI GLYC 2007. [DOI: 10.4052/tigg.19.133] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
25
|
Rojas G, Lamdan H, Padron S, Munoz Y, Ayala M, Gavilondo JV. Efficient construction of a highly useful phage-displayed human antibody repertoire. Biochem Biophys Res Commun 2005; 336:1207-13. [PMID: 16169520 DOI: 10.1016/j.bbrc.2005.09.005] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2005] [Accepted: 09/01/2005] [Indexed: 11/18/2022]
Abstract
We have constructed a highly useful phage-displayed human antibody repertoire with limited cloning efforts. Our strategy was to maximize diversity during the first steps of library construction through the use of various lymphoid sources from several donors, inclusion of different immunoglobulin isotypes, and performance of multiple separate amplification reactions with all possible combinations within a complex primer set. The resulting variable region collections were cloned to form a moderate size library, composed by 4.25x10(8) single chain antibody fragments. This repertoire was successfully used to retrieve binders to seven model antigens: six proteins and one 12 aa peptide. Binding affinities reached nanomolar and even subnanomolar range. Sequence diversity and V-gene usage variability among binders were proven. Our approach was not focused on absolute library size, but on a high quality sampling of variable regions from the human antibody repertoire.
Collapse
Affiliation(s)
- Gertrudis Rojas
- Recombinant Antibodies Laboratory, Pharmaceuticals Division, Center for Genetic Engineering and Biotechnology, Playa, La Habana, Cuba.
| | | | | | | | | | | |
Collapse
|
26
|
Goodchild S, Love T, Hopkins N, Mayers C. Engineering Antibodies for Biosensor Technologies. ADVANCES IN APPLIED MICROBIOLOGY 2005; 58C:185-226. [PMID: 16543034 DOI: 10.1016/s0065-2164(05)58006-7] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Affiliation(s)
- Sarah Goodchild
- Dstl, Detection Department, Porton Down Salisbury, Wiltshire SP4 OJQ, United Kingdom
| | | | | | | |
Collapse
|